Showing 1 to 12 of 12 results
Johnson & Johnson Faces DEI Lawsuit
America First Legal (AFL) is urging the Department of Health and Human Services to investigate Johnson & Johnson for allegedly violating federal law with its DEI hiring practices, citing the Civil Rights Act of 1964 and a Trump executive order, while Johnson & Johnson denies any wrongdoing.
Johnson & Johnson Faces DEI Lawsuit
America First Legal (AFL) is urging the Department of Health and Human Services to investigate Johnson & Johnson for allegedly violating federal law with its DEI hiring practices, citing the Civil Rights Act of 1964 and a Trump executive order, while Johnson & Johnson denies any wrongdoing.
Progress
60% Bias Score
Unsolved Tylenol Murders: New Documentary Examines Suspect's Final Interview
The Netflix documentary "Cold Case: The Tylenol Murders" revisits the unsolved 1982 poisonings in Chicago, featuring a final interview with suspect James Lewis, who died in 2023, and exploring the impact on public health and ongoing investigation.
Unsolved Tylenol Murders: New Documentary Examines Suspect's Final Interview
The Netflix documentary "Cold Case: The Tylenol Murders" revisits the unsolved 1982 poisonings in Chicago, featuring a final interview with suspect James Lewis, who died in 2023, and exploring the impact on public health and ongoing investigation.
Progress
56% Bias Score
Judge Rejects Johnson & Johnson's Third Bankruptcy Attempt over Talc Lawsuits
A US federal judge rejected Johnson & Johnson's third attempt to use bankruptcy to create a $11 billion trust fund for women claiming talc-related cancer, citing irregularities in the approval process where only 75% of claimants approved the deal. The judge stated that the best course of action was ...
Judge Rejects Johnson & Johnson's Third Bankruptcy Attempt over Talc Lawsuits
A US federal judge rejected Johnson & Johnson's third attempt to use bankruptcy to create a $11 billion trust fund for women claiming talc-related cancer, citing irregularities in the approval process where only 75% of claimants approved the deal. The judge stated that the best course of action was ...
Progress
40% Bias Score
J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.
J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.
Progress
36% Bias Score
FDA Proposes Asbestos Testing for Talc-Based Cosmetics
The U.S. Food and Drug Administration (FDA) proposed a rule requiring manufacturers to test talc-containing cosmetics for asbestos, following Congressional legislation and public health concerns stemming from past contamination incidents and significant litigation, such as the $700 million settlemen...
FDA Proposes Asbestos Testing for Talc-Based Cosmetics
The U.S. Food and Drug Administration (FDA) proposed a rule requiring manufacturers to test talc-containing cosmetics for asbestos, following Congressional legislation and public health concerns stemming from past contamination incidents and significant litigation, such as the $700 million settlemen...
Progress
48% Bias Score
Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.
Dow Jones Stocks Poised for Growth in 2025: Merck and Nvidia Lead the Way
Wall Street analysts predict strong gains for select Dow Jones stocks in 2025, with Merck leading at 32% projected upside due to its Keytruda drug and pipeline, while Nvidia projects 28% growth despite recent market corrections; other pharma stocks show mixed outlooks.
Progress
40% Bias Score
Netflix Documentary Explores Unsolved Tylenol Murders
The Netflix documentary "Cold Case: The Tylenol Murders" revisits the 1982 Chicago deaths caused by cyanide-laced Tylenol, featuring an exclusive interview with long-suspected James Lewis, who died shortly after filming, and the resulting changes to consumer product safety regulations.
Netflix Documentary Explores Unsolved Tylenol Murders
The Netflix documentary "Cold Case: The Tylenol Murders" revisits the 1982 Chicago deaths caused by cyanide-laced Tylenol, featuring an exclusive interview with long-suspected James Lewis, who died shortly after filming, and the resulting changes to consumer product safety regulations.
Progress
40% Bias Score
Spanish Court Holds Johnson & Johnson and AEMPS Liable for Faulty Hip Implants
A Spanish court case holds Johnson & Johnson and the Spanish Medicines Agency (AEMPS) responsible for injuries caused by faulty ASR hip implants, highlighting regulatory failures and lack of patient monitoring.
Spanish Court Holds Johnson & Johnson and AEMPS Liable for Faulty Hip Implants
A Spanish court case holds Johnson & Johnson and the Spanish Medicines Agency (AEMPS) responsible for injuries caused by faulty ASR hip implants, highlighting regulatory failures and lack of patient monitoring.
Progress
44% Bias Score
Major Earnings Reports to Shape Wall Street's Short Week
This week, 35 S&P 500 companies, including Netflix, Johnson & Johnson, and United Airlines, will release earnings reports following a week of strong bank earnings, with 76% of the already reported companies beating analyst expectations. Key factors to watch include Netflix's content strategy, United...
Major Earnings Reports to Shape Wall Street's Short Week
This week, 35 S&P 500 companies, including Netflix, Johnson & Johnson, and United Airlines, will release earnings reports following a week of strong bank earnings, with 76% of the already reported companies beating analyst expectations. Key factors to watch include Netflix's content strategy, United...
Progress
24% Bias Score
Market Volatility Boosts Demand for High-Quality Dividend Stocks
Amidst market volatility with the S&P 500 and Nasdaq experiencing their longest losing streaks since April, UBS highlights high-quality dividend stocks in the U.S., Japan, and other regions, noting regional differences in dividend growth and safety.
Market Volatility Boosts Demand for High-Quality Dividend Stocks
Amidst market volatility with the S&P 500 and Nasdaq experiencing their longest losing streaks since April, UBS highlights high-quality dividend stocks in the U.S., Japan, and other regions, noting regional differences in dividend growth and safety.
Progress
36% Bias Score
FDA Proposes Stricter Talc Testing Amidst Cancer Lawsuits
The FDA proposed stricter asbestos testing for talc in cosmetics following a 2023 Congressional mandate, prompted by lawsuits and despite recent negative FDA test results on 150 samples since 2021; the rule aims to improve consumer confidence.
FDA Proposes Stricter Talc Testing Amidst Cancer Lawsuits
The FDA proposed stricter asbestos testing for talc in cosmetics following a 2023 Congressional mandate, prompted by lawsuits and despite recent negative FDA test results on 150 samples since 2021; the rule aims to improve consumer confidence.
Progress
56% Bias Score
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Progress
36% Bias Score
Showing 1 to 12 of 12 results